Status:

RECRUITING

Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria

Lead Sponsor:

Cystinose Stiftung

Collaborating Sponsors:

Screening Laboratory Hannover

Pediatry Kastanienhof Koeln

Conditions:

Cystinosis

Primary Hyperoxaluria

Eligibility:

All Genders

32-72 years

Phase:

NA

Brief Summary

In Germany parents of newborns are offered newborn screening (NBS) for 17 congenital diseases as a standard benefit of statutory health insurance. NBS in Germany is voluntary. Cystinosis and hyperoxal...

Detailed Description

Background and aims. Population-based newborn screening (NBS) is an important public health program that has vastly improved the course of several diseases through early detection. The selection of sc...

Eligibility Criteria

Inclusion Criteria:

  • Newborns participating at the NGS with parent's consent to participate in this screening project

Exclusion Criteria:

  • Newborns without parent's consent to participate in this screening project.

Key Trial Info

Start Date :

March 15 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2026

Estimated Enrollment :

200000 Patients enrolled

Trial Details

Trial ID

NCT05843851

Start Date

March 15 2022

End Date

June 30 2026

Last Update

May 6 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Screening Laboratory Hanover

Hanover, Lower Saxony, Germany, 30430

Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria | DecenTrialz